Medivir and Tibotec forge ahead with Hep C compound
This article was originally published in Scrip
Executive Summary
Medivir and Tibotec Pharmaceuticals have launched the Phase III programme for their once-daily oral protease inhibitor TMC435 for the treatment of hepatitis C. The development pushes the product into third place in the race to provide a new antiviral alternative for hepatitis C patients.